Stock comparison
AbbVie Inc. is 161.3x more valuable than Immunome Inc. by market capitalization ($441.54 B vs $2.74 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 161.3x more valuable than Immunome Inc. by market capitalization ($441.54 B vs $2.74 B).
Market value leader
ABBV
AbbVie Inc. is 161.3x more valuable than Immunome Inc. by market capitalization ($441.54 B vs $2.74 B).
Revenue leader
ABBV
IMNM: $6.94M vs ABBV: $61.16B.
Profit leader
ABBV
IMNM: -$212.39M vs ABBV: $4.23B.
Margin leader
ABBV
IMNM: -3060.0% vs ABBV: 6.9% net margin.
| Metric | IMNM | ABBV |
|---|---|---|
| Market cap | $2.74 B | $441.54 B |
| US-listed rank | #1911 | #25 |
| Revenue (latest FY) | $6.94M | $61.16B |
| Net income (latest FY) | -$212.39M | $4.23B |
| Net margin | -3060.0% | 6.9% |
| P/E (trailing FY) | - | 104.5x |
| SEC filings | 413 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 161.3x more valuable than Immunome Inc. by market capitalization ($441.54 B vs $2.74 B).
In their latest fiscal years, Immunome Inc. reported $6.94M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Immunome Inc. and AbbVie Inc., or browse the full rankings.